Adverse effect · Semax

How common is safety in humans with Semax?

D
Grade D — no human evidenceNo systematic international data · effect size: not measurable · adverse
Short answerNo human evidence. As of 2 September 2026, only no systematic international data exist for Semax for safety in humans. Long Russian clinical use is reassuring but not equivalent to pharmacovigilance data.

What the studies show

Long Russian clinical use is reassuring but not equivalent to pharmacovigilance data.

Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.

In context

Semax is a seven-amino-acid peptide derived from ACTH, developed in Russia in the 1980s and registered there for stroke and cognitive indications. It is not approved in the EU, US or UK. The human literature is almost entirely Russian-language, largely uncontrolled or poorly reported by international standards, and has not been replicated by independent groups — which is why the cognitive and stroke claims sit at grade D despite the registration.

Semax is not approved (outside russia). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Semax proven to cause safety in humans?
No. There is no human evidence for it (No systematic international data); the claim rests on animal or cell studies and LYO grades it D.
What studies are behind the grade?
Long Russian clinical use is reassuring but not equivalent to pharmacovigilance data.
Is Semax approved for this?
No. Semax is not approved (outside Russia); it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for Semax

Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →